A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
← catalyst calendarNCT06587828 · readout ≤ 165 d
Sponsored by TScan Therapeutics, Inc. (industry) · TCRX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-03 | actual | When the study began enrolling |
| Primary completion | Jan 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Autoimmune Diseases
- Ulcerative Colitis
- Multiple Sclerosis
- Scleroderma
- Ankylosing Spondylitis
- Celiac Disease
- Non-radiographic Axial Spondyloarthritis (Nr-axSpA)
- Crohn&Amp;#39;s Disease
- Birdshot Chorioretinitis
Intervention
- Procedure: Companion blood samples with procedure
Primary outcome
what the primary-completion date above is the date OFIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study.
measured 3 Years
Permalink · TCRX's whole pipeline · Catalyst calendar · Every registered study · What changed